Skip to main content
Lancet (London, England)
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
Challenges and opportunities in developing integrated sexual and reproductive health programmes.
A turning point for global health: challenge or opportunity?
Regional action needed to halt antimalarial drug resistance in Africa.
Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
Seizing opportunities to end TB: a call for ambition and optimism on World TB Day.
Building a tuberculosis-free world while responding to the COVID-19 pandemic.
Are three drugs for malaria better than two?
